News and Announcements
Allowance of Phylogica’s US Patent for Synthetic Phylomer Libraries
- Published October 02, 2013 12:14PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- US Patent allowed for rationally designed synthetic Phylomer libraries
- Broad applications of synthetic Phylomer libraries in therapeutics and diagnostics
- Patent allowance further secures Phylogica’s ownership of the entire Phylomer peptide class
- New patent greatly extends life of Phylogica’s core patent estate – out to November 2027
- Phylogica is already in discussion with prospective partners interested in accessing this technology
PERTH, AUSTRALIA: October 2nd, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces the allowance of its US patent application for synthetic Phylomer libraries. This core patent (designated USSN 11/672,419) covers generic methods of designing synthetic Phylomer peptide libraries based on the identification of parts of natural proteins, which are predicted to form structures independently when isolated from the parent protein from which they are derived. The patent also contains methods for maximising the diversity of such structures represented in the library.
To read the full ASX Release please click on the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
